Article thumbnail

Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex®) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion

By Annie Chan, Loh-Shan Leung and Mark S Blumenkranz

Abstract

Macular edema is a common cause of visual loss in patients with retinal vein occlusions. Ozurdex®, a dexamethasone intravitreal implant, has been shown in randomized controlled trials to reduce macular edema and improve visual acuity in patients with either branch retinal vein occlusions or central retinal vein occlusions. It was approved in the United States in 2009. Since then, new therapeutic agents and clinical data have emerged. The purpose of this review is to critically evaluate the clinical utility of Ozurdex® in the current treatment strategy of macular edema related to retinal vein occlusion

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3151568
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs Aging.
  2. (1985). Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules.
  3. Differentiating intraocular glucocorticoids.
  4. (2004). Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res.
  5. (2005). Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol.
  6. (1992). Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol.
  7. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema.
  8. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.
  9. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes.
  10. (1991). Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci.
  11. Nonsteroidal and steroidal anti-inflammatory agents.
  12. Patients’ preferences in choosing therapy for retinal vein occlusions.
  13. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci.
  14. (2007). Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol.
  15. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
  16. Ranibizumab for macular edema following branch retinal vein occlusion.
  17. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
  18. Ranibizumab for macular edema following central retinal vein occlusion.
  19. (2006). Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res.
  20. Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion.
  21. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion.
  22. (1995). The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report. Ophthalmology
  23. The prevalence of retinal vein occlusion: pooled data from population studies from the United States,
  24. (1991). Toxicity of high-dose intravitreal dexamethasone. Int Ophthalmol.
  25. (2003). Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol.
  26. Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire.